No Data
LIFETECH SCI: ANNUAL REPORT 2024
The industry is hotly discussing the future trends of nuclear medicine, will Hybrid NewCo become a new model for the RDC Industry to venture abroad? | Industry Observation
① Today, the 2025 Future XDC New Drug Conference is held in Chengdu; ② Executives from companies such as Baillie Tianheng and Kelun Botai, along with numerous experts and scholars in the industry, will jointly discuss cutting-edge technologies in ADC/nuclear drug development, overseas strategies, and other Topics.
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Do Its Financials Have Any Role To Play In Driving LifeTech Scientific Corporation's (HKG:1302) Stock Up Recently?
Press Release: LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 Billion, and International Business Increased by 26%
LifeTech Scientific Corporation (HKG:1302) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
